| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (NCT05208307) | Emory University | 2022-07-21 |
| Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma (NCT05312255) | Roswell Park Cancer Institute | 2022-06-28 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma (NCT05288062) | Mayo Clinic | 2022-06-15 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (NCT05005299) | Melbourne Health | 2022-06-08 |
| Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization (NCT04211259) | Rutgers, The State University of New Jersey | 2022-04-18 |
| Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy (NCT05204160) | Emory University | 2022-04-11 |
| Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant (NCT05274763) | Emory University | 2022-03-21 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors (NCT05142371) | City of Hope Medical Center | 2021-10-06 |
| SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer (NCT04977024) | GeoVax, Inc. | 2021-09-27 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma (NCT04782687) | US Oncology Research | 2021-09-10 |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study (NCT05053100) | Mayo Clinic | 2021-08-17 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma (NCT04892264) | Mayo Clinic | 2021-06-03 |
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy (NCT04465760) | OHSU Knight Cancer Institute | 2021-02-25 |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial (NCT04566328) | ECOG-ACRIN Cancer Research Group | 2021-02-24 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma (NCT04530812) | Roswell Park Cancer Institute | 2020-08-24 |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (NCT04458831) | Sanofi | 2020-08-13 |
| Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (NCT04270409) | Sanofi | 2020-06-16 |
| Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure (NCT04352205) | Emory University | 2020-05-07 |
| DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer (NCT04282343) | Barbara Ann Karmanos Cancer Institute | 2020-02-25 |
| Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation (NCT02700841) | University of Nebraska | 2020-01-09 |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies (NCT05011045) | M.D. Anderson Cancer Center | 2020-01-09 |
| Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission (NCT04221178) | Memorial Sloan Kettering Cancer Center | 2020-01-03 |
| Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma (NCT03793907) | Roswell Park Cancer Institute | 2019-12-17 |
| Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma (NCT03870451) | Wake Forest University Health Sciences | 2019-11-01 |
| Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma (NCT04100044) | Thomas Jefferson University | 2019-10-24 |
| Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation (NCT03417284) | M.D. Anderson Cancer Center | 2019-10-09 |
| First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma (NCT04000282) | Sanofi | 2019-08-19 |
| Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT03346135) | City of Hope Medical Center | 2019-07-17 |
| Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT03942224) | Emory University | 2019-07-03 |
| Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma (NCT03870633) | Alliance for Clinical Trials in Oncology | 2019-05-14 |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma (NCT03858205) | University of Southern California | 2019-03-11 |
| Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma (NCT03756896) | Emory University | 2019-01-25 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (NCT04065789) | Tel-Aviv Sourasky Medical Center | 2018-05-02 |
| Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma (NCT03477539) | Mayo Clinic | 2018-04-09 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis (NCT03303950) | University of Utah | 2018-03-30 |
| Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma (NCT03311828) | City of Hope Medical Center | 2018-02-21 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (NCT03194867) | Sanofi | 2018-02-21 |
| A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (NCT03319667) | Sanofi | 2017-12-07 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (NCT03275285) | Sanofi | 2017-10-25 |
| Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (NCT03317899) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-10-12 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma (NCT03119883) | Mayo Clinic | 2017-06-02 |
| Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer (NCT03141437) | M.D. Anderson Cancer Center | 2017-04-23 |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT03012880) | Mayo Clinic | 2017-04-20 |
| SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (NCT02334865) | Roswell Park Cancer Institute | 2017-04-13 |
| Daratumumab in Treating Patients With Multiple Myeloma (NCT02944565) | Ohio State University Comprehensive Cancer Center | 2017-02-22 |
| Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy (NCT03078452) | Emory University | 2017-02-14 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant (NCT02880228) | Mayo Clinic | 2016-09-16 |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma (NCT02492750) | Mayo Clinic | 2016-04-01 |
| Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT02619682) | Fred Hutchinson Cancer Center | 2015-12-30 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation (NCT02513186) | Sanofi | 2015-09-30 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma (NCT02514668) | Sanofi | 2015-09-01 |
| Lenalidomide Maintenance in Plasma Cell Myeloma (NCT02538198) | Memorial Sloan Kettering Cancer Center | 2015-08-31 |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (NCT02283775) | Sanofi | 2015-05-15 |
| Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant (NCT02389517) | University of Chicago | 2015-03-02 |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma (NCT02057640) | Jason Valent | 2014-05-22 |
| Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT01863550) | ECOG-ACRIN Cancer Research Group | 2013-12-06 |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (NCT01919619) | M.D. Anderson Cancer Center | 2013-11-04 |
| Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis (NCT01864018) | Mayo Clinic | 2013-08-20 |
| Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01729091) | M.D. Anderson Cancer Center | 2013-06-10 |
| SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients (NCT01749969) | Sanofi | 2013-02-06 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT01718743) | M.D. Anderson Cancer Center | 2012-12-03 |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma (NCT01547806) | National Cancer Institute (NCI) | 2012-02-22 |
| 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01503242) | Fred Hutchinson Cancer Center | 2012-01-09 |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT01055301) | SWOG Cancer Research Network | 2011-07-01 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01251575) | Fred Hutchinson Cancer Center | 2010-12-01 |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT02353572) | University of Colorado, Denver | 2009-11-01 |
| Dalteparin in Preventing DVT in Participants With Cancer (NCT00525057) | M.D. Anderson Cancer Center | 2006-07-07 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis (NCT00064337) | SWOG Cancer Research Network | 2004-01-01 |
| Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (NCT00075478) | Fred Hutchinson Cancer Center | 2003-10-01 |
| Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (NCT00096161) | Fred Hutchinson Cancer Center | 2003-05-01 |
| S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma (NCT00900263) | SWOG Cancer Research Network | 2002-06-01 |